Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc (NQ: XENE )

35.05 +1.06 (+3.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 528,335
Open 33.62
Bid (Size) 34.99 (4)
Ask (Size) 35.05 (3)
Prev. Close 33.99
Today's Range 33.06 - 35.25
52wk Range 24.94 - 41.39
Shares Outstanding 63,037,991
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
From Xenon Pharmaceuticals Inc.
Via Globe NewsWire
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via Globe NewsWire

Performance

YTD
-5.93%
-5.93%
1 Month
-8.56%
-8.56%
3 Month
-7.03%
-7.03%
6 Month
-2.39%
-2.39%
1 Year
+18.17%
+18.17%

More News

Read More
Earnings Scheduled For March 1, 2023
Via Benzinga
Xenon Pharmaceuticals Earnings Preview
Via Benzinga
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via Globe NewsWire
The Latest Analyst Ratings for Xenon Pharmaceuticals
Via Benzinga
Analyst Ratings for Xenon Pharmaceuticals
Via Benzinga
Xenon Pharmaceuticals Earnings Perspective: Return On Capital Employed
Via Benzinga
Where Xenon Pharmaceuticals Stands With Analysts
Via Benzinga
Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Xenon Pharmaceuticals Inc.
Via Globe NewsWire
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
Via Investor's Business Daily
Applied UV (NASDAQ: AUVI) Effectively Doubles Its Size Following A Merger That Could Help Shape The Industry – A Brief Look At The Company
Via Benzinga
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
From Xenon Pharmaceuticals Inc.
Via Globe NewsWire
Xenon Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022)
From Xenon Pharmaceuticals Inc.
Via Globe NewsWire
Xenon Pharmaceuticals to Present at the Bank of America Securities Biotech SMID Cap Conference 2022
From Xenon Pharmaceuticals Inc.
Via Globe NewsWire
Xenon Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For November 28, 2022
Via Benzinga
Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences
From Xenon Pharmaceuticals Inc.
Via Globe NewsWire
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
Via Investor's Business Daily
Xenon Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via Globe NewsWire
Earnings Scheduled For November 8, 2022
Via Benzinga
Earnings Preview: Xenon Pharmaceuticals
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.